Selective granulocyte and monocyte apheresis (GMA) as a non-pharmacological option, has shown promising efficacy and higher safety in the treatment of patients with ulcerative colitis (UC). The GMA can not only promote healing of intestinal mucosa and improve the clinical remission rate, prolong the time of clinical alleviate [1], to reduce the recurrence rate, but also have certain effect to control the extra-intestinal accompanying symptoms [2,3]. Compared with conventional therapy, GMA has shown promising efficacy and higher safety in the treatment of patients with ulcerative colitis (UC).
